AbCellera Biologics (ABCL) Accumulated Depreciation & Amortization (2020 - 2025)
Historic Accumulated Depreciation & Amortization for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $5.2 million.
- AbCellera Biologics' Accumulated Depreciation & Amortization fell 8578.78% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 8578.78%. This contributed to the annual value of $39.7 million for FY2024, which is 6281.21% up from last year.
- As of Q3 2025, AbCellera Biologics' Accumulated Depreciation & Amortization stood at $5.2 million, which was down 8578.78% from $5.5 million recorded in Q2 2025.
- AbCellera Biologics' Accumulated Depreciation & Amortization's 5-year high stood at $39.7 million during Q4 2024, with a 5-year trough of $4.8 million in Q1 2024.
- Over the past 5 years, AbCellera Biologics' median Accumulated Depreciation & Amortization value was $13.2 million (recorded in 2022), while the average stood at $16.8 million.
- As far as peak fluctuations go, AbCellera Biologics' Accumulated Depreciation & Amortization surged by 15870.03% in 2021, and later tumbled by 8578.78% in 2025.
- Over the past 5 years, AbCellera Biologics' Accumulated Depreciation & Amortization (Quarter) stood at $14.5 million in 2021, then surged by 92.67% to $27.8 million in 2022, then decreased by 12.38% to $24.4 million in 2023, then soared by 62.81% to $39.7 million in 2024, then tumbled by 86.79% to $5.2 million in 2025.
- Its Accumulated Depreciation & Amortization was $5.2 million in Q3 2025, compared to $5.5 million in Q2 2025 and $5.3 million in Q1 2025.